Seung Cheol Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Seung Cheol Kim has a total of 243 co-authors. Here are the top co-authors by number of shared publications:
Woong Ju
Innovative Research Center for Control and Prevention of Women's Cancer, Ewha Womans University Mokdong Hospital, Yangcheon-gu, Seoul Korea
13 shared publications- Yun Hwan Kim
Department of Obstetrics and Gynecology, Ewha Womans University College of Medicine, Seoul, Republic of Korea
10 shared publications - Jae-Weon Kim
Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea
6 shared publications - Kyung-Hee Kim
Department of Applied Chemistry, School of Science and Technology, Kookmin University, Seoul 02707, Republic of Korea
5 shared publications Soo Yoon Lee
Department of Obstetrics and Gynecology, Hanmaeum Changwon Hospital, Changwon, Kyungnam, Korea
5 shared publicationsYun Hwan Kim
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Ewha Womans University Mokdong Hospital, Ewha Womans University School of Medicine, Seoul, Korea
5 shared publications
Latest Publications
- Open Access
- 1 January 2021
- Published by XMLink in Journal of Korean Medical Science
- Vol. 36 (45)
Effect of Quality Control Program in Surgical Management of Early Cervical Cancer
Shim JE, et al. J Korean Med Sci. 2021 Nov;36(45):e316. https://doi.org/10.3346/jkms.2021.36.e316
- 1 January 2021
- Published by XMLink in Journal of Korean Medical Science
- Vol. 36 (45)
Open AccessEffect of Quality Control Program in Surgical Management of Early Cervical Cancer
Shim JE, et al. J Korean Med Sci. 2021 Nov;36(45):e316. https://doi.org/10.3346/jkms.2021.36.e316
- Open Access
- 1 January 2021
- Published by XMLink in Journal of Korean Medical Science
- Vol. 36 (38)
Disparities between Uptake of Germline BRCA1/2 Gene Tests and Implementation of Post-test Management Strategies in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients
Hur YM, et al. J Korean Med Sci. 2021 Aug;36(38):e241. https://doi.org/10.3346/jkms.2021.36.e241
- 1 January 2021
- Published by XMLink in Journal of Korean Medical Science
- Vol. 36 (38)
Open AccessDisparities between Uptake of Germline BRCA1/2 Gene Tests and Implementation of Post-test Management Strategies in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients
Hur YM, et al. J Korean Med Sci. 2021 Aug;36(38):e241. https://doi.org/10.3346/jkms.2021.36.e241
- Open Access
- 25 March 2020
- Published by Seventh Sense Research Group Journals in International Journal of Veterinary Science
- Vol. 6 (1) , 1-5
Evaluation of the Performance of Interferon Gamma Assays for the Diagnosis of Bovine Tuberculosis in Hanwoo beef cattle in Korea
Evaluation of the Performance of Interferon Gamma Assays for the Diagnosis of Bovine Tuberculosis in Hanwoo beef cattle in Korea
- 25 March 2020
- Published by Seventh Sense Research Group Journals in International Journal of Veterinary Science
- Vol. 6 (1) , 1-5
Open AccessEvaluation of the Performance of Interferon Gamma Assays for the Diagnosis of Bovine Tuberculosis in Hanwoo beef cattle in Korea
Evaluation of the Performance of Interferon Gamma Assays for the Diagnosis of Bovine Tuberculosis in Hanwoo beef cattle in Korea
- Open Access
- 1 January 2019
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 30 (5) , e104
Minimally invasive surgery for radical hysterectomy in women with cervical cancer: Korean Society of Gynecologic Oncology, Korean Society of Obstetrics and Gynecology, and Korean Society of Gynecologic Endoscopy and Minimally Invasive Surgery position statement
Kim M, et al. J Gynecol Oncol. 2019 Jul;30(5):e104. https://doi.org/10.3802/jgo.2019.30.e104
- 1 January 2019
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 30 (5) , e104
Open AccessMinimally invasive surgery for radical hysterectomy in women with cervical cancer: Korean Society of Gynecologic Oncology, Korean Society of Obstetrics and Gynecology, and Korean Society of Gynecologic Endoscopy and Minimally Invasive Surgery position statement
Kim M, et al. J Gynecol Oncol. 2019 Jul;30(5):e104. https://doi.org/10.3802/jgo.2019.30.e104
- Open Access
- 1 January 2019
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 30 (4) , e91
The 34th Annual Meeting of the Korean Society of Gynecologic Oncology 2019: meeting report
Yim GW, et al. J Gynecol Oncol. 2018 Aug;30:e91. https://doi.org/10.3802/jgo.2019.30.e91
- 1 January 2019
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 30 (4) , e91
Open AccessThe 34th Annual Meeting of the Korean Society of Gynecologic Oncology 2019: meeting report
Yim GW, et al. J Gynecol Oncol. 2018 Aug;30:e91. https://doi.org/10.3802/jgo.2019.30.e91
- Open Access
- 1 January 2019
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 30 (2) , e39
Asian Society of Gynecologic Oncology International Workshop 2018
Kong TW, et al. J Gynecol Oncol. 2018 Aug;30:e39. https://doi.org/10.3802/jgo.2019.30.e39
- 1 January 2019
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 30 (2) , e39
Open AccessAsian Society of Gynecologic Oncology International Workshop 2018
Kong TW, et al. J Gynecol Oncol. 2018 Aug;30:e39. https://doi.org/10.3802/jgo.2019.30.e39
- Open Access
- 15 July 2018
- Published by Korean Cancer Association in Cancer Research and Treatment
- Vol. 50 (3) , 883-893
Profiling of Serum Metabolites Using MALDI-TOF and Triple-TOF Mass Spectrometry to Develop a Screen for Ovarian Cancer
We sought to develop a matrix assisted laser desorption ionization-time of flight (MALDI-TOF)-based, ovarian cancer (OVC), low-mass-ion discriminant equation (LOME) and to evaluate a possible supportive role for triple-TOF mass analysis in identifying metabolic biomarkers. A total of 114 serum samples from patients with OVC and benign ovarian tumors were subjected to MALDI-TOF analysis and a total of 137 serum samples from healthy female individuals and patients with OVC, colorectal cancer, hepatobiliary cancer, and pancreatic cancer were subjected to triple-TOF analysis. An OVC LOME was constructed by reference to the peak intensity ratios of discriminatory low-mass ion (LMI) pairs. Triple-TOF analysiswas used to select and identify metabolic biomarkers for OVC screening. Three OVC LOMEs were finally constructed using discriminatory LMI pairs (137.1690 and 84.4119 m/z; 496.5022 and 709.7642 m/z; and 524.5614 and 709.7642 m/z); all afforded accuracies of > 90%. The LMIs at 496.5022 m/z and 524.5614 m/z were those of lysophosphatidylcholine (LPC) 16:0 and LPC 18:0. Triple-TOF analysis selected seven discriminative LMIs; each LMI had a specificity > 90%. Of the seven LMIs, fourwith a 137.0455 m/z ion atretention times of 2.04-3.14 minuteswere upregulated in sera from OVC patients; the ion was identified as that derived from hypoxanthine. MALDI-TOF-based OVC LOMEs combined with triple-TOF-based OVC metabolic biomarkers allow reliable OVC screening; the techniques are mutually complementary both quantitatively and qualitatively.
- 15 July 2018
- Published by Korean Cancer Association in Cancer Research and Treatment
- Vol. 50 (3) , 883-893
Open AccessProfiling of Serum Metabolites Using MALDI-TOF and Triple-TOF Mass Spectrometry to Develop a Screen for Ovarian Cancer
We sought to develop a matrix assisted laser desorption ionization-time of flight (MALDI-TOF)-based, ovarian cancer (OVC), low-mass-ion discriminant equation (LOME) and to evaluate a possible supportive role for triple-TOF mass analysis in identifying metabolic biomarkers. A total of 114 serum samples from patients with OVC and benign ovarian tumors were subjected to MALDI-TOF analysis and a total of 137 serum samples from healthy female individuals and patients with OVC, colorectal cancer, hepatobiliary cancer, and pancreatic cancer were subjected to triple-TOF analysis. An OVC LOME was constructed by reference to the peak intensity ratios of discriminatory low-mass ion (LMI) pairs. Triple-TOF analysiswas used to select and identify metabolic biomarkers for OVC screening. Three OVC LOMEs were finally constructed using discriminatory LMI pairs (137.1690 and 84.4119 m/z; 496.5022 and 709.7642 m/z; and 524.5614 and 709.7642 m/z); all afforded accuracies of > 90%. The LMIs at 496.5022 m/z and 524.5614 m/z were those of lysophosphatidylcholine (LPC) 16:0 and LPC 18:0. Triple-TOF analysis selected seven discriminative LMIs; each LMI had a specificity > 90%. Of the seven LMIs, fourwith a 137.0455 m/z ion atretention times of 2.04-3.14 minuteswere upregulated in sera from OVC patients; the ion was identified as that derived from hypoxanthine. MALDI-TOF-based OVC LOMEs combined with triple-TOF-based OVC metabolic biomarkers allow reliable OVC screening; the techniques are mutually complementary both quantitatively and qualitatively.
- Open Access
- 8 December 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 9 (5) , 5979-5992
Src is the primary target of aripiprazole, an atypical antipsychotic drug, in its anti-tumor action
Src is the primary target of aripiprazole, an atypical antipsychotic drug, in its anti-tumor action Src is the primary target of aripiprazole, an atypical antipsychotic drug, in its anti-tumor action
- 8 December 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 9 (5) , 5979-5992
Open AccessSrc is the primary target of aripiprazole, an atypical antipsychotic drug, in its anti-tumor action
Src is the primary target of aripiprazole, an atypical antipsychotic drug, in its anti-tumor action Src is the primary target of aripiprazole, an atypical antipsychotic drug, in its anti-tumor action
- 24 October 2017
- Published by Wiley in Diagnostic Cytopathology
- Vol. 46 (1) , 15-21
Aberrant single‐minded homolog 1 methylation as a potential biomarker for cervical cancer
Background: The aim of this study is to evaluate the possibility of using the methylation status of single‐minded homolog 1 (SIM1) as a diagnostic biomarker for cervical cancer.Methods: All the patient and normal specimens including the normal cervix (n = 10), cervical cancer tissues (n = 45), blood (n = 45), and cervical brush specimens (n = 110) were retrospectively obtained. Quantitative methylation‐specific PCR was performed to detect SIM1 methylation in primary tumors, cervical brush specimens, and plasma circulating cell‐free DNA (ccfDNA). SIM1 expression was detected by western blot analysis.Results: We found that SIM1 was highly methylated in the majority of the cervical cancer tissues that we tested, but not in any of the normal tissues. Hypermethylation of SIM1 led to a pronounced reduction in SIM1 expression in cervical cancer tissues compared with normal cervix. SIM1 methylation status on cervical brush specimens also distinguished cervical cancer from normal, cervical intraepithelial neoplasia (CIN) 1 and 2. The degree of SIM1 methylation was significantly associated with the severity of the disease (Ptrend < .0001). We also investigated the possibility of detecting methylated SIM1 in plasma ccfDNA from cervical cancer patients. Methylated SIM1 was detected in 36.6% (15/41) of ccfDNA samples, and concordance rate with the matched cancer tissues was 41.5% (17/41) with sensitivity 38.5% and specificity 100%.Conclusion: This study has shown that SIM1 is frequently hypermethylated in cervical cancer, compared with normal cervix tissue, CIN1 and 2 samples, suggesting that the methylation status of SIM1 could be a potential diagnostic biomarker for cervical cancer.
- 24 October 2017
- Published by Wiley in Diagnostic Cytopathology
- Vol. 46 (1) , 15-21
Aberrant single‐minded homolog 1 methylation as a potential biomarker for cervical cancer
Background: The aim of this study is to evaluate the possibility of using the methylation status of single‐minded homolog 1 (SIM1) as a diagnostic biomarker for cervical cancer.Methods: All the patient and normal specimens including the normal cervix (n = 10), cervical cancer tissues (n = 45), blood (n = 45), and cervical brush specimens (n = 110) were retrospectively obtained. Quantitative methylation‐specific PCR was performed to detect SIM1 methylation in primary tumors, cervical brush specimens, and plasma circulating cell‐free DNA (ccfDNA). SIM1 expression was detected by western blot analysis.Results: We found that SIM1 was highly methylated in the majority of the cervical cancer tissues that we tested, but not in any of the normal tissues. Hypermethylation of SIM1 led to a pronounced reduction in SIM1 expression in cervical cancer tissues compared with normal cervix. SIM1 methylation status on cervical brush specimens also distinguished cervical cancer from normal, cervical intraepithelial neoplasia (CIN) 1 and 2. The degree of SIM1 methylation was significantly associated with the severity of the disease (Ptrend < .0001). We also investigated the possibility of detecting methylated SIM1 in plasma ccfDNA from cervical cancer patients. Methylated SIM1 was detected in 36.6% (15/41) of ccfDNA samples, and concordance rate with the matched cancer tissues was 41.5% (17/41) with sensitivity 38.5% and specificity 100%.Conclusion: This study has shown that SIM1 is frequently hypermethylated in cervical cancer, compared with normal cervix tissue, CIN1 and 2 samples, suggesting that the methylation status of SIM1 could be a potential diagnostic biomarker for cervical cancer.